Long-acting bronchodilators have an extended ... possible clinical effects and may not target all components of COPD. Another bronchodilator, theophylline, has proven efficacy and an anti ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to ...

GOLD guidelines recommend using these for patients with recurrent exacerbations or moderate COPD adjunct therapy to a long-acting bronchodilator. Yet, more than one fourth of surveyed physicians ...

Current treatments for COPD include one anti-inflammatory medication and two long-acting medications that are also bronchodilators. These treatments are often taken in combination, depending on ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.

A total of 2,802 patients with COPD were randomised 1:1 to receive ... and could include single or dual long-acting bronchodilator therapy, inhaled corticosteroid either alone or in combination ...

Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

The Bronchodilator Drugs market in South Korea is forecasted to achieve a revenue of US$0.37bn in 2024. It is expected to exhibit a compound annual growth rate (CAGR) of 3.99% from 2024 to 2029 ...